Immunotherapy Offers Alternative to Surgery for High-Risk Bladder Cancer Patients

A clinical trial published in The Lancet Oncology found that the novel immunotherapy, Crytostemogen Grenadineribvic, enabled 81% of 115 high-risk bladder cancer patients to avoid bladder removal surgery for two years. This development offers a promising alternative for individuals whose standard treatments have failed, potentially improving patient outcomes and quality of life by preventing radical surgical intervention.